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Abstract 
Multiple Sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) 
in which the body’s immune system attacks the fatty myelin sheath surrounding neurons, 
resulting in impaired neuronal signaling. Myelin-specific CD4 effector T cells (Teff) are 
pathogenic while CD4 T regulatory cells (Treg) are advantageous by suppressing Teff cells in 
both MS and its murine model, experimental autoimmune encephalomyelitis (EAE). Th17 cells 
are a major subset of Teff cells that mediate the formation of acute inflammatory CNS lesions 
and disease progression in EAE. Th17 cells are also implicated in MS pathogenesis. We focused 
on the Interleukin (IL)-6/STAT3 pathway in MS pathogenesis, as dysregulation of this pathway 
is observed in MS patients. IL-6 is a cytokine that signals through the transcription factor STAT3 
to induce the development of Th17 cells, which produce a proinflammatory cytokine, IL-17. 
Moreover, IL-6 suppresses the generation of inducible Tregs (iTregs) and facilitates the Teff 
resistance to Treg-mediated suppression in MS patients, skewing the Teff:Treg balance towards 
Teff cells. This evidence suggests targeting STAT3 signaling may provide therapeutic benefit for 
MS. We developed a novel small molecule inhibitor, LLL12b, of STAT3. In previous studies, 
we found that LLL12b suppresses Th17 development and promotes iTreg development of 
murine and human CD4 T cells. In this study, we examined whether LLL12b could suppress the 
resistance of Teff cells from MS patients to Treg-mediated suppression. Using a CFSE-based 
suppression assay, our data show that LLL12b increases the Treg-mediated suppression on Teff 
cells, which may shift the functional Teff:Treg balance towards Tregs. Taken together, our novel 
small molecule STAT3 inhibitor may normalize the Teff:Treg balance of CD4 T cells and 
provide a novel therapeutic strategy for ameliorating disease progression in MS. 
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Introduction 
 The human immune system defends against infectious microbes as well as noninfectious 
foreign substances, products of damaged cells, and, under some circumstances, self-molecules. 
The immune system defends against microbes by using innate or adaptive immune responses. 
Innate immunity occurs within the first few hours or days after infection and utilizes mechanisms 
that are inherently present in the body, which allow for rapid responses. In contrast, adaptive 
immune responses occur several days after infection and increase in magnitude and defensive 
capabilities with each subsequent exposure to a particular microbe, or antigen1.  
 The major class of cells involved in the adaptive immune response are lymphocytes, 
which consist of B cells and T cells. B cells are part of humoral immunity (one type of the 
adaptive immune response), and they block infections and eliminate extracellular microbes by 
secreting antibodies. Another type of adaptive immune response, called cell-mediated immunity, 
is mediated by T cells. There are mainly two types of T cells: helper T (Th) cells activate other 
immune cells to kill phagocytosed microbe and cytotoxic T lymphocytes (CTLs) directly destroy 
infected cells. B cells and T cells can be distinguished by the expression of cell surface proteins 
designated by a “CD” number. Most Th cells express CD4, whereas most CTLs express CD8. 
Lymphocytes also express specific antigen receptors, which allow the immune system to 
recognize and respond to millions of foreign antigens1. As myelin-specific CD4 T effector cells 
drive the formation of acute inflammatory demyelinating lesions and clinical relapses in the EAE 
model of MS, only CD4 T cells will be described further.  
 T cells originate from stem cells in the bone marrow and mature in the thymus. After 
maturation, T cells recirculate in the peripheral blood and secondary lymphoid organs, waiting 
until they come in contact with an antigen. When these circulating naïve T cells encounter an 
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antigen, a signaling cascade event occurs in which the T cells secrete cytokines, proliferate, and 
differentiate into effector cells, which are capable of eliminating the antigen1,2. Depending on the 
antigen, co-stimulators, and cytokines, naïve CD4 T cells can differentiate into distinct subsets of 
effector cells and produce different cytokines based on the transcription factor that is 
characteristically expressed (Figure 1). Th1 cells are produced in response to activation of the 
transcription factors STAT1, STAT4, and T-bet via interferon-γ (IFN-γ) and interleukin-12 (IL-
12) signaling. Th1 cells are the major Teff subset involved in macrophage activation, which 
results in phagocytosis of microbes. Th2 cells develop when IL-4 activates STAT6, and they 
mainly function to promote eosinophil- and mast cell-mediated reactions to eliminate infection 
and promote tissue repair by producing IL-4, IL-5, and IL-13.  A third subset of CD4 Teff cells 
are Th17 cells, which produce IL-17 in response to IL-6, IL-1, and IL-231. The development of 
Th17 cells is dependent on STAT3 activation, as endogenous Th17 cells are absent in STAT3-/- 
mice3. Th17 cells mainly recruit neutrophils to sites of infection, producing inflammation to 
eliminate bacterial and fungal microbes1. Previous studies have shown that Th1 and Th17 subsets 
of CD4 T effector cells are encephalitogenic in EAE and are implicated in MS pathogenesis4,5. 
 Self-tolerance refers to the ability of the immune system to recognize self-antigens but 
not respond to them, and this property is essential for the functioning of a normal immune 
system. Most thymic-derived CD4 T cells with high affinity for self-antigens are targeted for 
deletion, but some of these T cells differentiate into Tregs that inhibit Teff responses to self-
antigens. CD4 Tregs express high levels of CD25, the IL-2 receptor α chain, and a transcription 
factor called forkhead box protein 3 (Foxp3)1. In experimental settings, naïve T cells in the 
periphery can also acquire Foxp3 expression. For instance, in the presence of TGF-β, retinoic 
acid (RA), and IL-2, naïve T cells are induced to differentiate into FoxP3+ iTregs in-vitro6,7,8,9. 
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iTregs are typically present at mucosal surfaces and are essential for oral tolerance, although they 
have also been observed in the spinal cords of mice with experimental autoimmune 
encephalomyelitis10. The balance between Teff:Treg cells is critical for the normal function of 
the immune system, since a Teff:Treg balance skewed towards Teffs favors autoimmunity.  
 MS is the most common cause of neurologic disability in young adults after trauma, with 
recent reports estimating a prevalence of nearly 750,000 cases in the United States alone11. Age 
of onset ranges from 20-40 years old, and women are affected 2-3 times more than men11,12. MS 
is also more frequent in regions at a higher latitude, though this gradient has been decreasing 
over the last five decades11,13. MS is a heterogeneous disease and consists of three main 
subtypes: relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary 
progressive MS (SPMS). RRMS is characterized by periods of attacks of neurologic symptoms 
followed by periods of partial or full recovery, and approximately 85% of people with MS are 
initially diagnosed with RRMS. SPMS follows an initial relapsing-remitting course and 
transitions into progressive worsening of symptoms, whereas PPMS is characterized by an 
accumulation of neurologic disability from the onset of symptoms, without any remissions. The 
formation of gadolinium-enhancing lesions in the brain and spinal cord correlate with symptoms, 
including fatigue, numbness or tingling, vision problems, and weakness, among other things14.  
 Initiation and progression of MS occurs in three stages: inflammation, demyelination, and 
axonal damage. The disease process is mediated by autoreactive CD4 T cells that target myelin 
proteins. Normally, the blood brain barrier (BBB) blocks entry from T cells in the periphery, but 
cell surface molecules on activated T cells allow migration across the BBB. Once in the CNS, 
the T cells must be reactivated to mediate pathology. Antigen-presenting cells (APCs), including 
dendritic cells, macrophages, microglia, or B cells, process proteins into peptide fragments and 
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present them to T cells, mainly through major histocompatibility complex class II. Finally, T 
cells are reactivated and produce cytokines, such as IFN-γ or IL-17, which in turn activate 
microglia and macrophages. The recruitment of T cells, microglia, and macrophages results in 
the formation of lesions in the gray and white matter. Microglia and macrophages produce other 
inflammatory mediators that, in addition to the cytokines, can damage myelin. Without any 
myelin, axons remain exposed and are subject to transection, leading to neuronal death12,15. 
 There are currently 15 FDA-approved disease-modifying therapies (DMTs) available to 
MS patients, including injectables, oral drugs, and monoclonal antibodies. Injectable drugs, like 
interferon beta and glatiramer acetate, are safer than other DMTs available but are not as 
efficacious. Oral drugs, such as dimethyl fumarate and fingolimod, and monoclonal antibodies, 
such as natalizumab and alemtuzumab, have higher efficacy, but they can cause serious adverse 
events, including progressive multifocal leukoencephalopathy (PML), a potentially fatal, viral 
infection of the brain16,17. In addition to side effects, patients often experience unpleasant 
reactions after injections and infusions, highlighting the need for novel oral therapies. 
  Dysregulation of the IL-6/STAT3 signaling pathway plays an important role in the 
pathogenesis of MS and other autoimmune diseases. IL-6 is elevated in plasma18 while IL-6 
mRNA and protein levels are elevated in the CNS of MS patients19,20. In addition, B cells from 
MS patients secrete significantly more IL-6 than healthy controls (HC)21. CD4 T cells from MS 
patients have significantly more IL-6 receptors (IL-6R) than HC22 and the expression of 
phosphorylated STAT3 (pSTAT3) in peripheral blood mononuclear cells (PBMC) from RRMS 
patients strongly correlates with MS disease activity23. These pieces of evidence suggest 
targeting STAT3 may normalize dysregulated IL-6/STAT3 signaling and provide therapeutic 
benefits for MS patients. 
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  IL-6/STAT3 signaling is a key regulator of Teff:Treg balance of CD4 T cells. IL-6 binds 
to the IL-6  receptor alpha (IL6-Rα) and GP130 on naïve CD4 T cells to form an IL-6/IL-
6Rα/GP130 heterodimer2,24,25. Two heterodimers form an active heterohexameric signaling 
complex, leading to downstream STAT3 activation and Th17 development3. In turn, Th17 cells 
produce the pro-inflammatory cytokine IL-17, which is pathogenic in MS and EAE5,26. 
Additionally, activation of the IL-6/STAT3 signaling pathway blocks the development of iTregs. 
For instance, IL-6/STAT3 signaling in murine CD4 T cells inhibits the induction of FoxP3- into 
FoxP3+ Tregs in-vivo27. As a result, dysregulated IL-6/STAT3 signaling skews Teff:Treg 
balance toward an enhanced Teff response, favoring the development of autoimmunity. In-vitro 
derived iTregs are functionally suppressive in EAE28 and can be used to augment and restore 
regulatory networks in situations where nTregs are exhausted or defective29. iTregs can also be 
generated in large numbers and regulate inflammation by direct suppression of endothelial 
activation and leukocyte recruitment30, making them an important tool in the treatment of 
autoimmune diseases. Recent studies have shown that Teff cells are resistant to Treg-mediated 
suppression in MS and other autoimmune diseases. In particular, Teff cell resistance involves IL-
6/STAT3 signaling. For example, Schneider et al. (2013) observed increased IL-6Rα expression 
and elevated IL-6 signaling as measured by pSTAT3 in RRMS subjects, and blockade of 
pSTAT3 restored functional suppression of Teff cells by Tregs31,32.  
 We have developed LLL12b, a novel small molecule inhibitor of STAT3 that binds to the 
SH2 domain of STAT3, preventing STAT3 phosphorylation and dimerization (Figure 3). As a 
small molecule, LLL12b has the potential to penetrate the BBB and may offer enhanced 
suppression of encephalitogenic T cells in the CNS. We have previously shown that LLL12b 
reduces IL-17 production and promotes iTreg development in mice with EAE and in human 
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peripheral blood mononuclear cells (PBMCs). Thus, we hypothesized that by inhibiting STAT3, 
LLL12b could restore iTreg-mediated suppression on Teff cells and normalize the balance of 
Teff:Treg of CD4 T cells from MS patients. To test our hypothesis, we performed 
carboxyfluorescein succinimidyl ester- (CFSE) based suppression assays. CFSE is a cell stain 
used to track multiple generations of cell division and proliferation (Figure 4). We determined if 
LLL12b improves iTreg-mediated suppression of murine myelin-specific CD4 T cells as well as 
PBMCs from treatment-naïve MS patients. 
 
Methods 
Generation of murine iTregs: 
 Splenocytes were isolated from three B6 mice and incubated for 72 hours with 500 u/mL 
recombinant mouse IL-2 (rmIL-2), 5 ng/mL rhTGF-β, and 10 nM RA on a 24-well plate coated 
with anti-mouse CD3/CD28 antibodies. After 72 hours, the cells were collected in a 50 mL 
conical tube, and the plate was washed with warm PBS to collect any remaining cells. Some cells 
were used for flow cytometry, and the rest of the cells were used for the suppression assay. 
Labelling myelin-specific CD4 T cells with CFSE: 
  Splenocytes from three 2D2 mice that are specific for MOG 35-55 were isolated and 
resuspended in a 50 mL conical tube with PBS at a concentration of 20x106/mL. CFSE was 
diluted in PBS to a final concentration of 100 uM. The diluted CFSE (100 uM) was added to 
2D2 splenocytes that made the final concentration of CFSE 5 uM. The CFSE-cell suspension 
was then incubated in a 37oC water bath for 10-15 minutes. PBS was added at 9x the original 
volume to the cells, and the cells were spun down at 1300 rpm for 8 minutes at 23oC. Cells were 
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washed again with 10 mL of PBS and spun down using the same settings mentioned previously. 
The cells were resuspended to a final volume of 2x106/mL.  
Murine suppression assay: 
 The CFSE-labelled cells from 2D2 mice were mixed with 10 ug/mL MOG 35-55, and 25 
ng/mL rmIL-6. The iTregs were collected, counted, and resuspended in EAE media at a 
concentration of 2x106/mL. The CFSE-2D2 cells and iTregs were aliquoted to a 24-well plate in 
the following Teff:Treg ratios: 1:0, 1:1, 2:1, and 4:1. DMSO was added to the control wells for 
vehicle control. The diluted LLL12b was added to half of the experimental wells for a final 
concentration of 0.25 uM and the other half of the experimental wells for a final concentration of 
0.5 uM. The cells were incubated for 4 days. % suppression was determined as 100-(% 
proliferating CFSE+ cells in each ration/% proliferating CFSE+ cells without Tregs)100. 
 
Recovery of frozen PBMCs: 
 Peripheral blood mononuclear cells (1x108) from three treatment-naïve MS patients were 
taken out of liquid nitrogen and put in a 37oC water bath immediately. Cells were transferred into 
cold PBS after thawing and spun down at 1300 rpm for 8 minutes at 4oC. The cells were washed 
again with cold PBS and spun down at 1300 rpm for 8 minutes at 4oC. Next, cells were 
resuspended in 20 mL of human medium and transferred to a 75 mm flask/patient. Cells 
incubated for 2 hours at 37oC. After the incubation period, the cells were passed through a 
strainer and spun down at 1300 rpm for 8 minutes at 23oC. Cells were resuspended in 2 mL of 
human medium and counted.  
Generation of human iTregs: 
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 15 ng/mL rhIL-2 and 10 nM RA were added to a mix containing isolated human PBMCs, 
human media, and 5 ng/mL rhTGF-β1. The cell mix was pipetted onto a 48-well plate (1 mL per 
well) and incubated for 72 hours at 37oC.  
 Labelling PBMCs with CFSE. CFSE was diluted in PBS to a final concentration of 100 
uM. The diluted CFSE (100 uM) was added to PBMCs that made the final concentration of 
CFSE at 1 uM. The CFSE-cell suspension was incubated in a 37oC water bath for 15 minutes. 
PBS was added at 9x the original volume to the cells, and the cells were spun down at 1300 rpm 
for 8 minutes at 23oC. Cells were washed again with 10 mL of PBS and spun down using the 
same settings mentioned previously. Cells were resuspended in human medium.  
 Pre-treatment of Teff cells with LLL12b. LLL12b was diluted to a concentration of 0.25 
uM, and DMSO was used as a control. CFSE-labelled Teff cells were resuspended in human 
medium and incubated for one hour at 37oC in a 24-well plate with rhIL-6 and LLL12b or 
DMSO. After incubation, cells were collected into a 15 mL conical tube, and the plate was 
washed with 1 mL of human medium and collected into each tube. The cells were spun down at 
1300 rpm for 8 minutes at 23oC and resuspended in human medium.  
Human suppression assay: 
 iTregs were collected and counted and aliquoted with the DMSO- or LLL12b-treated 
CFSE cell mix onto an anti-human (αh) CD3/CD28 coated 48 well plate (1 mL/well) according 
to the following ratios of Teff:Treg: 4:1, 8:1, and 16:1. There was also a condition containing 
only CFSE-labelled Teff cells, which was used to monitor the natural proliferation of Teff cells. 
The cells were incubated for 5 days at 37oC. % suppression was determined as 100-(% 
proliferating CFSE+ cells in each ration/% proliferating CFSE+ cells without Tregs)100. 
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Flow cytometry 
Surface Staining: 
 Murine cells or PBMCs from culture were microcentrifuged at 2000 rpm for 1 minute at 
23oC. The supernatant was vacuumed out, and the pellets were resuspended in 50-100 uL of 
staining buffer (1% BSA in PBS). The cells were then stained with surface antibodies and Fc-
block for 30 minutes at 4oC in the dark and washed three times with staining buffer. Cells were 
resuspended in 200 uL of staining buffer and transferred to FACS tubes. 80,000-100,000 live cell 
events were acquired on a FACSCantoII and analyzed using FlowJo software. 
Intracellular staining for Foxp3: 
 Murine cells or PBMCs were surface stained as described previously. After the staining 
period, the cells were washed three times with staining buffer and then fixed and permeabilized 
using a 1x fix/perm buffer (eBioscience) for 60 minutes on ice in the dark. The cells were then 
washed twice with staining buffer and placed in a 4oC fridge overnight. The following day, 1x 
perm/wash buffer was added (eBioscience), and the cells were placed on ice for 20 minutes in 
the dark. Next, the cells were washed one time with 1x perm/wash buffer and then intracellularly 
stained with an antibody mix consisting of Foxp3 and Fc-block for 30 minutes on ice in the dark. 
After incubating, the cells were washed three times with 1x perm/wash buffer. After the last 
wash, the cells were resuspended in 200 uL of 1x perm/wash buffer and transferred to FACS 
tubes. 80,000-100,000 live cell events were acquired on a FACSCantoII and analyzed using 
FlowJo software. 
Phospho staining: 
 Human PBMCs were recovered as described previously and aliquoted to a 24 well plate 
(1 mL/well) plus rhIL-6, and DMSO or 0.25 uM LLL12b and incubated for 30 minutes at 37oC. 
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1 mL of pre-warmed Fix/Perm Buffer (BD biosciences) was added to each well immediately 
after incubation. The cells were mixed, transferred to 15 mL conical tubes, and placed in a 37oC 
water bath for 10-12 minutes. Next, the cells were spun down at 600 G for 8 minutes at 23oC. 
The supernatant was vacuumed out, and the cells were vortexed to disrupt the cell pellet. 1 mL of 
chilled Perm Buffer III was slowly added to the cells to permeabilize them. The cells were 
vortexed and placed on ice for 30 minutes. 5 mL of stain buffer (0.5% FBS/PBS) was added to 
each tube and spun down at 600 G for 8 minutes at 4oC. The supernatant was vacuumed out, and 
400 uL of stain buffer was added to each tube. The cells were transferred to a flow plate, spun 
down at 2000 rpm for 2 minutes at 4oC, and washed three times with stain buffer. The cells were 
stained with either isotype control or pSTAT3 antibodies plus Fc-block for one hour at room 
temperature in the dark. The cells were washed three times, resuspended in 200 uL of stain 
buffer, and transferred to FACS tubes. 80,000-100,000 live cell events were acquired on a 
FACSCantoII and analyzed using FlowJo software. 
 
Results 
LLL12b enhances iTreg-mediated suppression of murine Th17 cells  
 We first examined whether LLL12b may enhance Treg-mediated suppression of murine 
myelin-specific Th17 cells using CFSE-based suppression assays. Splenocytes from three 
WT/B6 mice were activated with MOG 35-55 plus TGF-β, rmIL-2, and RA for 3 days to 
generate iTregs. The development of iTregs was determined by intracellular staining of Foxp3 
(Figure 4). The cells were collected and stained with viability dye and CD4 and CD25 
antibodies, followed by intracellular staining with Foxp3. Live CD4+ cells were gated on CD25 
(a marker of activated Tregs) and Foxp3 (an essential transcription factor expressed by Tregs) to 
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quantify iTregs. Meanwhile, splenocytes from three 2D2 mice that are specific for MOG 35-55 
were isolated and labeled with CFSE. We then co-cultured the iTregs with CFSE-labelled 
splenocytes from 2D2 mice at Teff:Treg ratios of 1:0, 4:1, 2:1, and 1:1 and activated them with 
MOG 35-55 and rmIL-6 for 4 days in the presence of DMSO, 0.25 uM LLL12b, or 0.5 uM 
LLL12b (Figure 6). The proliferation of MOG 35-55 specific CD4 T cells was determined by 
flow cytometric analysis of CFSE on CD4+ T cells (Figure 6a). The CFSE- population represents 
proliferating MOG 35-55 specific CD4 T cells while the CFSE+ population is not proliferating. 
Our data show that the proliferating CFSE- cells decrease (36%, 24%, and 21%) when there are 
more iTregs in the culture (Teff:Treg ratio: 4:1, 2:1, and 1:1) (Figure 6a, 6b). The highest amount 
of proliferation occurred when no Tregs were present (Teff:Treg ratio at 1:0), and the lowest 
amount of proliferation occurred at 2:1 and 1:1 (p<0.001), suggesting the iTregs we generated 
are functionally active by suppressing the proliferation of MOG 35-55-specific CD4 T cells. 
Furthermore, % proliferating cells were notably lower in LLL12b treated groups compared to 
vehicle control DMSO group (Figure 6c), suggesting LLL12b treatment leads to decreased 
proliferation. % suppression was determined as 100-(% proliferating CFSE+ cells in each ratio/% 
proliferating CFSE+ cells without Tregs)100. LLL12b significantly reduced Teff resistance to 
Treg-mediated suppression, as shown by % inhibition (Figure 6d). This data suggests that by 
inhibiting STAT3 in murine myelin-specific CD4 T cells, Treg-mediated suppression on Teff 
cells was improved.  
 
LLL12b inhibits the phosphorylation of STAT3 in CD4+ T cells from MS patients 
 To determine if LLL12b may suppress the resistance of human PBMCs from MS patients 
to Treg-mediated suppression, we first determined if LLL12b inhibits pSTAT3 in human CD4 T 
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cells from MS patients. PBMCs from 6 treatment-naïve MS patients were activated with plate 
bound αhCD3/CD28 plus rhIL-6 for 30 minutes, in the presence of 0.25 uM of LLL12b or 
DMSO. DMSO- and LLL12b-treated cells were stained with a CD4 surface antibody and either 
an isotype control antibody or a pSTAT3 antibody for one hour. To determine levels of pSTAT3 
in MS patients, we ran flow cytometry and focused on CD4+pSTAT3+ cells. pSTAT3+ cells 
represent CD4+ T cells in which the IL-6/STAT3 pathway is activated. Compared to our vehicle 
control, LLL12b significantly reduced levels of pSTAT3 (p<0.05), meaning LLL12b suppresses 
the phosphorylation of STAT3 in human CD4+ T cells from MS patients (Figures 7a). % 
pSTAT3+ cells in the DMSO and LLL12b-treated conditions was determined and compared for 
each patient. All MS patients showed a reduction in % pSTAT3+ CD4 T cells, with some patients 
exhibiting greater reductions than other patients (Figure 7b), indicating that LLL12b may be 
variably effective in suppressing STAT3 phosphorylation in human CD4 T cells from MS 
patients. This data suggests LLL12b suppresses activation of the IL-6/STAT3 signaling pathway.  
 
LLL12b reduces the resistance of CD4 T cells from MS patients to iTreg-mediated 
suppression 
 We examined whether LLL12b could restore Treg-mediated suppression on Teff cells by 
conducting CFSE-based suppression assays. Human PBMCs from 3 treatment-naïve MS patients 
were activated with plate bound αhCD3/CD28 plus rhTGF-β1, rhIL-2, and RA for 3 days to 
generate iTregs. The development of iTregs was determined by intracellular staining of Foxp3, 
as described previously. PBMCs from the same patients were labeled with CFSE and cultured 
with 0.25 uM of LLL12b or DMSO for 1-2 hours. The LLL12b-treated CD4 T cells were then 
mixed with iTregs generated from the same patients at Teff:Treg ratios of 1:0, 4:1, 8:1, and 16:1. 
15 
 
The proliferation of human Teff cells was determined by flow cytometric analysis of CFSE on 
CD4+ T cells. % suppression was determined as 100-(% proliferating CFSE+ cells in each 
ratio/% proliferating CFSE+ cells without Tregs)100. We found that Tregs suppress the 
proliferation of human CD4 T cells in a dose-dependent manner (Figure 8a). % non-proliferating 
CFSE+ cells increased (54%, 70%, and 76%) in the DMSO condition when there were more 
iTregs in the culture (Teff:Treg ratio 16:1, 8:1, 4:1), suggesting the human Tregs we generated 
are functionally active. LLL12b enhanced Treg-mediated suppression of Teff cells compared to 
DMSO, with optimal suppression occurring at a Teff:Treg ratio of 4:1, followed by 8:1 and 16:1. 
Suppression varied among patients, but all patients showed increased Treg-mediated suppression 
of Teff cells when given LLL12b compared to DMSO, even in the 16:1 condition (Figure 8c). 
This data suggests that Treg-mediated suppression on CD4 Teff cells from MS patients can be 
improved by inhibiting STAT3. 
 
Discussion 
  MS patients have a skewed Teff:Treg balance compared to healthy individuals, resulting 
in excessive Teff responses. The IL-6/STAT3 signaling pathway is a crucial regulator of the 
Teff:Treg balance, and aberrant signaling results in the production of highly encephalitogenic 
Th17 cells, blockage of iTreg development, and resistance of CD4 Teff cells to Treg-mediated 
suppression. We hypothesized that LLL12b, a novel small molecule STAT3 inhibitor, could 
enhance Treg suppressive function on Teff cells in CD4 T cells from MS patients. Our data 
supported our hypothesis in that LLL12b reduced resistance of CD4 Teff cells to Treg-mediated 
suppression. In murine CFSE-based suppression assays, we established that LLL12b promoted 
increased suppression of Teff cells when the Teff:Treg ratio was 2:1 and 4:1. LLL12b also 
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reduced Teff resistance to Treg-mediated suppression in PBMCs from treatment-naïve MS 
patients. We observed enhanced suppression of CD4 Teff cells by Tregs in a dose-dependent 
manner. The optimal ratio for suppressing CD4 Teff cells occurred at a Teff:Treg ratio of 4:1, 
followed by 8:1 and 16:1.  We also found that LLL12b significantly reduced pSTAT3 levels, 
indicating that we effectively targeted STAT3 rather than a downstream component of the IL-
6/STAT3 signaling pathway. Taken together, our data suggest that LLL12b has the potential to 
normalize the Teff:Treg balance in CD4 T cells and is a promising lead compound for the 
treatment of MS. 
 In the murine suppression assays, we added LLL12b into the culture containing CFSE-
labelled 2D2 cells and iTregs, meaning both Treg and Teff cell populations were exposed to 
LLL12b treatment. Although our previous experiments show LLL12b promotes Treg 
development in mice and human PBMCs, there is no TGF-β added to induce iTreg development 
during the suppression assays. Therefore, the possibility that LLL12b exerts its function through 
promoting iTreg development during the suppression assays is minimal. To rule out this 
possibility, we pretreated PBMCs with LLL12b, followed by co-culture of LLL12b-treated CD4 
T cells with iTregs for human suppression assays. In this way, we could be certain that LLL12b 
was directly exerting its effects on the Teff cell population.  
 It is important to note that the viability of frozen PBMC samples from MS patients 
presented a limitation to our study. Murine cells are relatively stable in culture, so we faced little 
difficulty in establishing the efficacy of LLL12b in murine cell culture. To test LLL12b in 
humans, we used cryopreserved PBMCs from MS patients. Unfortunately, cell viability after 
thaw is highly variable among patients; thus, we only utilized samples that were easily 
recoverable and generated enough cells to use through the entirety of the experiment. To increase 
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our external validity, we would like to run the same experiments with fresh PBMCs from MS 
patients, as the cell composition of frozen PBMCs is relatively similar to fresh PBMCs, so as to 
eliminate the detrimental recovery process. Even with this limitation, our data highlight the 
potential of targeting the IL-6/STAT3 signaling pathway to ameliorate CNS autoimmunity.  
 Most current DMTs for the treatment of RRMS come with a host of drawbacks. 
Injectable DMTs, such as IFN-β and glatiramer acetate, are safe and have been the first-line 
treatment options for two decades. However, they are only moderately effective and are poorly 
tolerated due to injection-related adverse events12. More recent DMTs have both higher efficacy 
and increased risk of serious adverse events like PML. Furthermore, monoclonal antibodies may 
not penetrate the CNS as effectively, limiting the suppression of CNS-infiltrating Teff cells and 
the promotion of Treg development in the CNS. Small molecules have the advantage of 
penetrating the BBB to directly exert their function, and an oral drug like LLL12b could 
eliminate the complications of injection or infusion-related reactions33. 
  Tocilizumab, a humanized αIL-6R monoclonal antibody, has proven efficacious for the 
treatment of rheumatoid arthritis34, giant cell arteritis35, and juvenile idiopathic arthritis36. 
Recently, our lab showed that three novel small molecule IL-6 inhibitors, madindoline-5 (MDL-
5), MDL-16, and MDL-101 suppress IL-17 production in myelin-specific CD4 T cells and 
promote iTreg development in-vitro33. confirming that targeting IL-6/STAT3 signaling may 
provide therapeutic benefits for MS.  
 Although loss of STAT3 in CD4 T cells prevents development of CNS inflammatory 
diseases, STAT3 is implicated in numerous other functions, including induction of an acute 
phase response in hepatoma cells, stimulation of proliferation of B cells, activation of terminal 
differentiation and growth arrest in monocytes, and maintenance of the pluripotency of 
18 
 
embryonic stem cells25. Furthermore, IL-10 requires STAT3 activation for its anti-inflammatory 
properties on macrophages37. Given that MS patients have unusually elevated IL-6/STAT3 
signaling, normalizing dysregulated STAT3 activation may provide better therapeutic effects 
with potentially fewer side effects. Because of the complex nature of STAT3, future studies 
could look at improving LLL12b’s bioavailability and drug delivery methods to more efficiently 
target CD4 T cells.  
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Figure 1. T cell differentiation. Naïve CD4+ T cells differentiate into Teff cells or Tregs 
depending on costimulatory factors38. 
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Figure 2. IL-6/STAT3 signaling regulates Th17:Treg balance. IL-6/STAT signaling inhibits 
Treg development and promotes excessive Teff cell responses. A skewed Teff:Treg balance 
toward Teff responses results in autoimmunity. 
 
  
 
Figure 3. Molecular structure and mechanism of action of LLL12b. LLL12b is a prodrug of 
LLL12 and binds to the SH2 domain of STAT3, preventing STAT3 phosphorylation and 
dimerization. 
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Figure 4. CFSE proliferation. (A) With each cell division, CFSE-labelled cells become 
progressively less fluorescent. (B) Dilution of the CFSE dye can be tracked by flow cytometry as 
cells proliferate over time. Numbers above the arrows represent each major cell division in 
CFSE-labelled human CD4+ T cells after 4 days of in-vitro stimulation39. 
 
 
Figure 5. Development of murine iTregs. First, we stained with viability dye to distinguish live 
and dead cells. The viable cells were gated on CD4, and the CD4+ cells were gated on CD25 (a 
marker of activated Tregs) and Foxp3 (an essential transcription factor expressed by Tregs). 
iTregs were defined as CD4+CD25+Foxp3+.  
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Figure 6: LLL12b enhances Treg-mediated suppression of myelin-specific CD4 T cells. 
Splenocytes from three B6 mice were activated with MOG 35-55 plus TGF-β, IL-2, and RA for 
3 days. The cells were then co-cultured with CFSE-labelled splenocytes from three 2D2 mice 
that are specific for MOG 35-55 at various ratios and activated with MOG 35-55 and rmIL-6 for 
4 days in the presence of DMSO, 0.25 uM, or 0.5 uM LLL12b. (A) Representative flow plot of 
DMSO-treated CD4 T cells. CFSE was determined by flow cytometry. (B) % proliferating 
CFSE+ cells were compared with one-way ANOVA (n=3) from (A). (C) % proliferating CFSE+ 
cells in DMSO- or LLL12b-treated groups at three Teff:Treg ratios from (A) was calculated. 
Represents data from one experiment (D) Combined % inhibition of CFSE+ cells in DMSO- or 
LLL12b-treated groups were compared with two-way ANOVA (n=3) at two Teff:Treg ratios. All 
error bars denote s.e.m. **p<0.01; ***p<0.001.  
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Figure 7. LLL12b inhibits the phosphorylation of STAT3 in CD4 T cells from MS patients. 
PBMCs from 6 treatment-naïve MS patients were activated with plate bound αhCD3/CD28 plus 
rhIL-6 for 30 minutes in the presence of 0.25 uM of LLL12b or DMSO. pSTAT3 was 
determined by flow cytometry. Cells were gated on CD4+ T cells. (A) Representative flow plot 
of pSTAT3 in LLL12b or DMSO-treated group from one MS patient. (B) pSTAT3 in LLL12b-
treated group and DMSO-treated group from 6 treatment-naïve MS patients were summarized 
and compared with Wilcoxon matched-pairs signed rank test for significance. *denotes p<0.05.  
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Figure 8. LLL12b reduces the resistance of CD4 T cells from MS patients to Treg-mediated 
suppression. PBMCs from three treatment-naïve MS patients were activated with αhCD3/CD28 
plus rhTGFβ, rhIL-2 and RA for 3 days to generate Tregs. PBMCs from the same patients were 
labeled with CFSE and cultured with 0.25μM of LLL12b or DMSO for 1-2hrs. The treated CD4 
T cells were mixed with iTregs generated from the same patient at four different ratios and 
cultured for 5 days. (A) Flow cytometric analysis of proliferation of CFSE-stained CD4+ T cells 
from one treatment-naïve MS patient. (B) % suppression by Tregs in DMSO- or LLL12b-treated 
group at three Teff:Treg ratios from (A) was calculated. (C) % suppression by iTregs in DMSO- 
or LLL12b-treated group from three MS patients (Teff:Treg=16:1) was summarized and 
compared with a paired Student’s t test. 
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